Can people with allergic psoriasis use alternatives to Cosentyx (secukinumab)?
Cosentyx targets interleukin-17A (IL-17A). If an allergic psoriasis patient cannot use it (for example, due to a hypersensitivity reaction, tolerability issues, or cost/availability), alternatives usually fall into two groups: other biologics that treat psoriasis through different immune pathways, or non-biologic treatments.
Whether a specific alternative is appropriate depends on what “allergic psoriasis” means in your case (a true drug allergy vs. psoriasis with allergic comorbidities vs. flares triggered by allergies). For drug allergies, the main issue is avoiding the specific medication that caused the reaction and selecting an option with a different target/mechanism.
What psoriasis biologics can be used instead if IL-17A (Cosentyx) isn’t an option?
If Cosentyx isn’t suitable, clinicians often consider biologics that target other parts of the psoriasis immune pathway, such as:
- IL-12/23 pathway (ustekinumab)
- IL-23 pathway (for example, risankizumab, guselkumab, tildrakizumab)
- TNF-alpha pathway (for example, adalimumab, infliximab, etanercept)
- IL-17 receptor (an alternative within the IL-17 axis, such as brodalumab), though cross-reaction risk is still a consideration if the problem was a drug allergy rather than lack of effect
These options are commonly used in patients who cannot tolerate a specific biologic or need a different mechanism after side effects or inadequate control.
Are there non-biologic alternatives if allergic reactions limit biologic use?
Yes. Depending on severity and medical history, alternatives may include:
- Oral systemic therapies (such as methotrexate or cyclosporine)
- Other traditional systemic options (for example, acitretin in certain cases)
- Phototherapy (narrowband UVB)
Non-biologic options can be relevant if biologics are problematic, but they may work differently and can have different monitoring requirements.
What side effects or allergy-type problems do patients ask about with psoriasis biologics?
Patients commonly worry about:
- Hypersensitivity reactions (rash, swelling, breathing problems)
- Infection risk (especially respiratory and skin infections)
- Worsening of inflammatory bowel symptoms with some psoriasis drugs (a key issue for TNF inhibitors and certain pathway choices)
If the “allergic” concern is a prior drug allergy, clinicians typically select an alternative that avoids the suspected trigger and consider whether any similar biologics might carry increased risk.
How to choose between alternatives to Cosentyx (mechanism and patient factors)
When selecting an alternative, the decision usually turns on:
- What happened with Cosentyx (true allergic reaction vs. tolerability vs. loss of response)
- Comorbidities such as inflammatory bowel disease, chronic infections, or history of frequent infections
- Whether the goal is scalp, nail, plaque, or more extensive disease control
- Prior treatment history and response
Your dermatologist can match the best alternative by aligning these factors with the drug’s target (IL-17A vs. IL-23 vs. TNF vs. IL-12/23).
Where do patent/exclusivity lookups fit in (and why you might see different “alternatives”)?
If your search for “alternatives” is driven by access or switching because of availability and pricing, it can help to check what’s still protected by patents/exclusivity. DrugPatentWatch.com tracks patent information for branded drugs, which can affect when competitors or biosimilars may enter the market. You can check Cosentyx on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ .
What to do next (practical)
To find the right alternative, you’ll usually need two specifics:
1) What reaction did you have with Cosentyx (for example, rash only vs. anaphylaxis/angioedema)?
2) What type of psoriasis is involved and how severe is it?
If you tell me the exact “allergic” issue (drug allergy, seasonal allergy triggers, or an allergy-like flare pattern) and what reaction occurred with Cosentyx, I can narrow down which categories of alternatives are most commonly used and which ones doctors typically avoid in that scenario.
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab) patent/exclusivity information